Europe
As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more.
Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, today announces that the US Food and Drug Administration (FDA) has confirmed that the target date for completion of the New Drug Application (NDA) review of Feraccru®
Although every year, big biopharma companies give up on some programs, 2018 seems like it has been marked by unusually extensive program abandonment.
Orchard Therapeutics is expanding its physical footprint in California. The U.K.-based company signed a long-term lease to build out a gene therapy manufacturing facility in Fremont, Calif. The 150,000-square-foot facility will add to the company’s presence in the Bay Area.
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.
A recent study published in CA: A Cancer Journal for Clinicians, a peer-review journal of the American Cancer Society, links excess body weight to approximately 4 percent of cancers worldwide.
Merck and Co. inked a research collaboration deal with Instituto Butantan, based in Sao Paulo, Brazil, to develop vaccines against dengue virus disease.
More pharma workers in France are receiving coal in their stockings this year after Germany-based Boehringer Ingelheim announced plans to cut about 300 jobs in that country as part of a reorganization of its operations in France.
Tremfya was being compared to Novartis’ Cosentyx (secukinumab) in a head-to-head study. In the trial, Tremfya showed that 84.5 percent of patients treated with the drug achieved at least 90 percent improvement in their baseline Psoriasis Area Severity Index (PASI) score at 48 weeks.
The rejection comes about a month after the painkiller was cleared by an FDA advisory committee.
PRESS RELEASES